Sorrento Therapeutics Inc. gained 17.75% today, following FDA approval of ZTlido, a next-generation non-opioid, lidocaine patch proposed for the relief of pain associated with post-herpetic neuralgia.
from RTT - Biotech http://ift.tt/2Fc8cd1
via IFTTT
No comments:
Post a Comment